The Tobias-Lechleiter Institute will focus on getting more Hoosiers enrolled in clinical trials and advancing medical research at IU Health and the IU School of Medicine.
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last month.
People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the medications.
The extended partnership holds the potential to be the largest industry-academic agreement of its kind in the United States, Purdue President Mung Chiang said.
The company has announced more than $50 billion in new U.S. manufacturing investments since 2020.
Chief Scientific Officer Dr. Daniel Skovronsky talked with the IBJ about his hopes for the Lilly Medicine Foundry, which the Indianapolis-based drugmaker broke ground on this week.
Officials from the Indianapolis-based drugmaker said the Lilly Medicine Foundry will help streamline the process of discovering new medicines and getting them to patients.
The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on existing tariff and trade policies.
By 2023, semaglutide (Ozempic, Rybelsus and Wegovy) and tirzepatide (Mounjaro) products made up 70% of all U.S. GLP-1 spending.
By making the expected blockbuster pill in the U.S., Lilly may be able to avoid the impact of Trump’s sweeping tariffs, including possible levies on pharmaceutical products.
Trial data data showed Lilly’s experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.
Trump’s order contains proposals to further lower the cost of insulin, importing more low-cost drugs and streamlining the federal approval process for some drugs.
It was the second straight sizable increase, suggesting that U.S. drug makers with Irish manufacturing hubs like Indianapolis-based Eli Lilly and Co. could be stockpiling products ahead of any tariffs on the sector.
Pfizer had been hoping the once-daily pill treatment would give it an edge over leading weight-loss treatments like Zepbound from Eli Lilly and Co. and Novo Nordisk’s Wegovy, which are injectable.
The drugmaker accuses Premier Weight Loss of risking patients’ health by selling altered, unsterile versions of its blockbuster drugs Mounjaro and Zepbound.
At least 14 states already cover the cost of GLP-1 medications for obesity treatment for patients on Medicaid. Indiana is not one of them.
President Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy.
Amid uncertainty around federal research funding, universities must explore private support, Purdue University President Mung Chiang told an tech industry group on Tuesday.
The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it.
The company said its goal is to reduce wait times for patients seeking access to specialists, creating more opportunities for early diagnosis and intervention.
